Docket No.: 023698-002US

(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

§

In Re Application of: F. Charles Brunicardi

Filed: Sept. 5, 2003

Serial No: 10/656,450

For: PROMOTER DRIVEN TISSUE

SPECIFIC CYTOTOXIC AGENTS

AND METHODS OF USE

Group Art Unit: 1632

Examiner: Sgagias, Magdalene K.

Confirmation No.: 8472

Publication No. US20050059620

Mail Stop RCE Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Sir:

RESPONSE TO OFFICE ACTION (FINAL) MAILED NOVEMBER 16, 2006 WITH REQUEST FOR CONTINUED EXAMINATION (RCE) UNDER 35 USC § 114

Applicant and Applicant's representative express their sincere appreciation to Examiners Magdalene Sgagias and Deborah Crouch for the telephonic interview of Friday, May 4, 2007.

As noted in the interview, Applicant is submitting this Response to the Office Action (Final) mailed November 16, 2006 with a Request for Continued Examination (RCE) under 35 USC § 114. As also noted in the interview, Applicant is further submitting as APPENDIX 2 a DECLARATION UNDER 37 CFR § 1.132 of F. CHARLES BRUNICARDI in order to address further the pending claim rejections made under 35 USC § 112, first paragraph.

Applicant authorizes the Director to charge Deposit Account No. 121322, Ref. No. 023698-002US (M. Gatschet), <u>for all</u> necessary small-entity fees [including, for the present Response, an RCE fee of \$395. $\frac{00}{}$, an extension-of-time fee of \$510. $\frac{00}{}$ for a three-month extension, a terminal disclaimer fee of \$130. $\frac{00}{}$, an Information Disclosure Statement (IDS) fee of \$180. $\frac{00}{}$, and a fee of \$350. $\frac{00}{}$ for fourteen new dependent claims (i.e., claims 140–153), which fees total \$1,565. $\frac{00}{}$ (i.e., \$395. $\frac{00}{}$ + \$510. $\frac{00}{}$ + \$130. $\frac{00}{}$ + \$180. $\frac{00}{}$ + \$350. $\frac{00}{}$)].